Premium
TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5‐FU
Author(s) -
Zhao Jian,
Zhang Xia,
Shi Mei,
Xu Hao,
Jin Jun,
Ni Haidong,
Yang Silei,
Dai Jianxin,
Wu Mengchao,
Guo Yajun
Publication year - 2006
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.21213
Subject(s) - cancer research , carcinogenesis , cytotoxic t cell , ectopic expression , hepatocellular carcinoma , cell culture , apoptosis , cell growth , cancer , liver cancer , biology , chemistry , medicine , in vitro , biochemistry , genetics
Abstract Hepatocellular carcinoma (HCC) is an aggressive cancer with a poor prognosis. The specific cellular gene alterations responsible for hepatocarcinogenesis are not well known. Previous works showed that loss of TIP30 , also called CC3 , a putative tumor suppressor, increased the incidence of hepatocellular carcinoma in mice, and some clinical samples of human HCC tissues had aberrant expression of TIP30 . Here, we report that the introduction of TIP30 by an adenovirus vector into HCC cell lines that had decreased expressions of TIP30 inhibited cell proliferation, decreased anchorage‐dependent growth, suppressed invasion through the extracellular matrix, and inhibited tumorigenesis in nude mice. Moreover, exogenous expression of Tip30 sensitized HCC cells to cytotoxic drugs and to apoptosis induced by tumor necrosis factor–related ligands in vitro. Ectopic expression of TIP30 in HCC cells enhanced p53 expression and decreased Bcl‐2/Bcl‐xL expression. Treatment of nude mice bearing subcutaneously established HCC tumors with a combination of an adenovirus expressing TIP30 and the cytotoxic drug 5‐fluorouracil completely suppressed tumor growth and prolonged survival. In conclusion , TIP30 may play an important role in the suppression of hepatocarcinogenesis by acting as a tumor suppressor. Overexpression of TIP30 might be a promising candidate as a treatment for HCC that would increase sensitivity to chemotherapeutic drugs. (H EPATOLOGY 2006;44:205–215.)